The U.S. uses almost half the world’s supply of moly‑99, but produces none.
The U.S. is completely dependent on foreign producers for molybdenum-99 (Mo-99 or moly-99; pronounced “molly-99”)–a medical ingredient used to diagnose and treat 56,000 American patients per day. Over 95% of global supply of moly‑99 is supplied from only four processing facilities located in Australia, Europe, and South Africa. Since moly-99 decays at a rate of approximately 1% per hour and cannot be stockpiled, without a domestic supply, American patients are relying on foreign governments to deliver the moly-99 they need. Help SHINE protect American patients.
SHINE’s advanced accelerator technology enables a high-yield molybdenum-99 (moly‑99 or Mo-99) production process that is safer, cleaner, more affordable and fits seamlessly into the existing moly-99 supply chain. Our process eliminates the need for a nuclear reactor and is free of weapons-grade (highly-enriched) uranium from beginning to end.
At SHINE we have a passion for using technology to make people’s lives better. We’re hiring the team to build the first moly-99 production and processing facility in the U.S. since the 1980s. Put your passion to work and be a part of the future of nuclear.